Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways

Wang，Tianxiang1; Zhang，Min1; Gong，Xinyu1; Chen，Wanjing2; Peng，Ying1; Liao，Chenzhong1; Xu，Hongmei1; Li，Qingshan1; Shen，Guodong3; Ren，Huirong3; Zhu，Yaxin4; Zhang，Baotong5; Mao，Jiali6; Wei，Lingling1; Chen，Yuanli1; Yang，Xiaoxiao1

2024-05-17

10.1016/j.isci.2024.109741

iScience   影响因子和分区

2589-0042

Pancreatic cancer (PC) is a lethal disease and associated with metabolism dysregulation. Nogo-B is related to multiple metabolic related diseases and types of cancers. However, the role of Nogo-B in PC remains unknown. In vitro, we showed that cell viability and migration was largely reduced in Nogo-B knockout or knockdown cells, while enhanced by Nogo-B overexpression. Consistently, orthotopic tumor and metastasis was reduced in global Nogo knockout mice. Furthermore, we indicated that glucose enhanced cell proliferation was associated to the elevation expression of Nogo-B and nuclear factor κB (NF-κB). While, NF-κB, glucose transporter type 1 (GLUT1) and sterol regulatory element-binding protein 1 (SREBP1) expression was reduced in Nogo-B deficiency cells. In addition, we showed that GLUT1 and SREBP1 was downstream target of NF-κB. Therefore, we demonstrated that Nogo deficiency inhibited PC progression is regulated by the NF-κB/GLUT1 and SREBP1 pathways, and suggested that Nogo-B may be a target for PC therapy.

Cancer Cell biology Molecular biology

SCI

英语

其他

2-s2.0-85191023549

Scopus

1.Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes,Anhui Provincial International Science and Technology Cooperation Base for Major Metabolic Diseases and Nutritional Interventions,College of Food and Biological Engineering,Hefei University of Technology,Hefei,230000,China
2.Department of General Surgery,The Second Affiliated Hospital,Anhui Medical University,Hefei,230000,China
3.Department of Geriatrics,The First Affiliated Hospital of University of Science and Technology of China,Gerontology Institute of Anhui Province,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,230000,China
4.Institute for International Health Professions Education and Research,China Medical University,Shenyang,110000,China
5.Department of Human Cell Biology and Genetics,School of Medicine,Southern University of Science and Technology,Shenzhen,518000,China
6.Department of Anesthesiology,The First Affiliated Hospital of University of Science and Technology of China,Hefei,230000,China

Wang，Tianxiang,Zhang，Min,Gong，Xinyu,et al. Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways[J]. iScience,2024,27(5).

Wang，Tianxiang.,Zhang，Min.,Gong，Xinyu.,Chen，Wanjing.,Peng，Ying.,...&Yang，Xiaoxiao.(2024).Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways.iScience,27(5).

Wang，Tianxiang,et al."Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways".iScience 27.5(2024).